Markets:

Overview

News

Currencies

International

Treasuries

Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

6.870 +0.120 (+1.78%)

Streaming Delayed Price Updated: 2:20 PM EDT, Aug 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Foghorn Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Crude Oil Up 1.5%; Philips Shares Jump After Q1 Results ↗

April 24, 2023

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16....

Via Benzinga

Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

April 24, 2023

Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment.

Via Benzinga

US Stocks Turn Lower; Nasdaq Dips 100 Points ↗

April 24, 2023

U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P...

Via Benzinga

Expert Ratings for Foghorn Therapeutics ↗

March 28, 2023

Via Benzinga

Foghorn Therapeutics Earnings Perspective: Return On Capital Employed ↗

March 15, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

October 20, 2022

Thursday saw 177 companies set new 52-week lows.

Via Benzinga

More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold ↗

April 24, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 24, 2023

Via Benzinga

Foghorn Therapeutics Provides an Update on FHD-609

April 24, 2023

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual

April 10, 2023

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting

April 06, 2023

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023 ↗

March 28, 2023

Via Benzinga

Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update

March 09, 2023

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference

March 01, 2023

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week ↗

February 16, 2023

Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.

Via The Motley Fool

Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023

January 09, 2023

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting

December 05, 2022

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

November 30, 2022

During Wednesday's session, 107 stocks hit new 52-week lows.

Via Benzinga

Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference

November 22, 2022

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting

November 14, 2022

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting

November 09, 2022

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update

November 08, 2022

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors

October 27, 2022

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program

October 26, 2022

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Foghorn Therapeutics to Present at Hanson Wade's 5th Annual Targeted Protein Degradation Summit

October 20, 2022

From Foghorn Therapeutics, Inc.

Via GlobeNewswire

Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session ↗

September 30, 2022

Gainers

Via Benzinga

Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session ↗

September 27, 2022

Gainers

Via Benzinga

Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday ↗

September 28, 2022

Gainers

Via Benzinga

Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday ↗

September 19, 2022

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.